MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson’s Disease

    N. Ito, J. Ozawa, K. Kataoka, K. Matsuoka, T. Nakanishi, T. Wada, A. Ishida, M. Kanemoto, T. Oguchi, M. Tsuji, Y. Kiuchi, H. Murakami (Tokyo, Japan)

    Objective: This study aims to identify pre-treatment indicators for Parkinson’s disease (PD) patients who respond well to monoamine oxidase type B inhibitors (MAOBIs). ​​​​​ Background: MAOBIs,…
  • 2025 International Congress

    Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…
  • 2025 International Congress

    Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers

    M. Minar, I. Straka, Z. Andre, M. Grofik, J. Necpal, M. Rusinkova, V. Han, Z. Kosutzka (Bratislava, Slovakia)

    Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Association between Freezing of Gait and Probable Sarcopenia in Patients with Parkinson’s Disease

    AP. Loureiro, K. Santos, J. Souza (Curitiba, Brazil)

    Objective: This study aimed to determine whether FOG is related to the risk of probable sarcopenia in PD patients. Sarcopenia is probable when low muscle…
  • 2025 International Congress

    Repetitive Transcranial Magnetic Stimulation For Freezing Of Gait And Motor Function In Parkinson’s Disease: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on motor function, freezing of gait (FOG), and mobility in patients with Parkinson’s disease…
  • 2025 International Congress

    Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301

    F. Moreira, L. Wojtecki, W. Jost, D. Santos Garcia, J. Kassubek, M. Fonseca, H. Brigas, G. Harrison-Jones, I. Pijuan (Duesseldorf, Germany)

    Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…
  • 2025 International Congress

    Coping with Parkinson’s Disease through the Lens of Personality Systems Interactions (PSI) Theory: Two Case Studies

    E. Wünnenberg, N. Baumann (Trier, Germany)

    Objective: This study examines how concepts from motivation and personality research contribute to understanding coping strategies in individuals with Parkinson’s disease (PD). Background: Effective treatment…
  • 2025 International Congress

    Smartphone-based digital assessments in the LUMA trial of BIIB122 for early-stage Parkinson’s disease

    R. Llorens Arenas, J. Edgerton, E. Bartholomé, S. Belachew, M. Gifford, J. Guo, B. Hersh, D. Jennings, C. Kanzler, E. Koca, M. Pang, O. Reyes, C. Shen, M. Wald, N. Woody, C. Mazzá (Cambridge, USA)

    Objective: To evaluate the sensitivity of routine smartphone-based performance assessments in the free-living environment as part of a randomized clinical trial in Parkinson’s disease (PD).…
  • 2025 International Congress

    IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 6-year Interim Results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…
  • « Previous Page
  • 1
  • …
  • 320
  • 321
  • 322
  • 323
  • 324
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley